2 active not recruiting, 2 recruiting, 1 not yet recruiting, 1 terminated. 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 2, Recruiting 2, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Active not recruiting 1, Not yet recruiting 1 |
Follow Lynch Syndrome: new trials by email Literature Review of Lynch Syndrome trials Research Report on Lynch Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventive Dendritic Cell Vaccination for Lynch Syndrome DC vaccination - Lynch Syndrome | Phase 1 / Phase 2 | Not yet recruiting | Radboud University Medical Center | 16 | 2026-10-01 | 2026-08-19 |
| Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection - Colorectal Carcinoma, Colorectal Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 186 | 2023-05-08 | 2026-11-12 |
| A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome Naproxen, Aspirin - T Cells, Colorectal Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2023-03-21 | 2026-11-05 |
| Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy - Colorectal Carcinoma, Lynch Syndrome | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 45 | 2022-11-10 | 2026-03-03 |
| Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome Mesalamine, Placebo - Lynch Syndrome, Colon Cancer | Phase 2 | Recruiting | Ann-Sofie Backman | 150 | 2022-03-21 | 2024-12-17 |
| Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) Omega-3 fatty acid ethyl esters (2 gram) - Colorectal Cancer, Lynch Syndrome | Phase 2 | Unknown | University of Kansas Medical Center | 21 | 2019-02-06 | 2023-06-01 |
| Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy Nivolumab - Colon Adenoma, Colon Carcinoma | Phase 2 | Terminated | John Hays | 3 | 2018-10-04 | 2024-07-01 |
Colorectal Neoplasms, Hereditary Nonpolyposis (7) · Colorectal Neoplasms (4) · Colonic Neoplasms (2)
Colonic Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · DNA Repair-Deficiency Disorders (7) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Gastrointestinal Diseases (7) · Gastrointestinal Neoplasms (7) · Genetic Diseases, Inborn (7) · Intestinal Diseases (7) · Intestinal Neoplasms (7) · Metabolic Diseases (7) · Neoplasms (7) · Neoplasms by Site (7) · Neoplastic Syndromes, Hereditary (7) · Nutritional and Metabolic Diseases (7)
Biopsy (2) · Specimen Handling (2) · Aspirin (1) · Colonoscopy (1) · Endoscopic Mucosal Resection (1) · Endoscopy (1) · Mesalamine (1) · Naproxen (1) · Nivolumab (1) · Omacor (1)
National Cancer Institute (NCI) (2) · Ann-Sofie Backman (1) · John Hays (1) · M.D. Anderson Cancer Center (1) · Radboud University Medical Center (1) · University of Kansas Medical Center (1)
United States (5) · Puerto Rico (2) · Denmark (1) · Netherlands (1) · Sweden (1)
Ajay Bansal (1) · Ann-Sofie Backman, MD PhD (1) · Anwaar Saeed, MD (1) · Eduardo Vilar-Sanchez (1) · Eduardo Vilar-Sanchez, MD (1) · John Hays, MD, Ph.D (1)
PMID 41213710, PMID 41545594, PMID 42238576
UG1CA242609 (2), P30CA016672 (1), P30CA060553 (1), R01CA257375 (1), UG1CA242596 (1), UG1CA242632 (1), UG1CA242635 (1), UG1CA242643 (1)